retinal pericytes Search Results


human retinal pericytes  (Innoprot Inc)
92
Innoprot Inc human retinal pericytes
Human Retinal Pericytes, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pm36484652-38-0-3?v=Innoprot+Inc
Average 92 stars, based on 1 article reviews
human retinal pericytes - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
htert  (Angio-Proteomie)
93
Angio-Proteomie htert
Htert, supplied by Angio-Proteomie, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pm38465502-203-12-27?v=Angio-Proteomie
Average 93 stars, based on 1 article reviews
htert - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
primary human retinal pericytes hrpcs  (Angio-Proteomie)
94
Angio-Proteomie primary human retinal pericytes hrpcs
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Primary Human Retinal Pericytes Hrpcs, supplied by Angio-Proteomie, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pm31361305-36-7-15?v=Angio-Proteomie
Average 94 stars, based on 1 article reviews
primary human retinal pericytes hrpcs - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
human telomerase reverse transcriptase htert  (Angio-Proteomie)
93
Angio-Proteomie human telomerase reverse transcriptase htert
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Human Telomerase Reverse Transcriptase Htert, supplied by Angio-Proteomie, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pm38465502-203-0-27?v=Angio-Proteomie
Average 93 stars, based on 1 article reviews
human telomerase reverse transcriptase htert - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
human retinal capillary pericytes  (Lonza)
90
Lonza human retinal capillary pericytes
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Human Retinal Capillary Pericytes, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pmc03260825-100-0-7?v=Lonza
Average 90 stars, based on 1 article reviews
human retinal capillary pericytes - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
bovine retinal pericytes  (Lonza)
90
Lonza bovine retinal pericytes
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Bovine Retinal Pericytes, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pmc02788982-29-0-7?v=Lonza
Average 90 stars, based on 1 article reviews
bovine retinal pericytes - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
primary human retinal pericyte cells  (CellSystems Biotechnologie Vertrieb GmbH)
90
CellSystems Biotechnologie Vertrieb GmbH primary human retinal pericyte cells
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Primary Human Retinal Pericyte Cells, supplied by CellSystems Biotechnologie Vertrieb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/us10730938-1334-14-21?v=CellSystems+Biotechnologie+Vertrieb+GmbH
Average 90 stars, based on 1 article reviews
primary human retinal pericyte cells - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
human retinal pericytes (rpcs)  (Lonza)
90
Lonza human retinal pericytes (rpcs)
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Human Retinal Pericytes (Rpcs), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pm27941324-51-0-7?v=Lonza
Average 90 stars, based on 1 article reviews
human retinal pericytes (rpcs) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
primary human retinal pericyte cells acbri 183  (CellSystems Biotechnologie Vertrieb GmbH)
90
CellSystems Biotechnologie Vertrieb GmbH primary human retinal pericyte cells acbri 183
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Primary Human Retinal Pericyte Cells Acbri 183, supplied by CellSystems Biotechnologie Vertrieb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/us10087246-1220-0-7?v=CellSystems+Biotechnologie+Vertrieb+GmbH
Average 90 stars, based on 1 article reviews
primary human retinal pericyte cells acbri 183 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
human retinal pericytes  (CellSystems Biotechnologie Vertrieb GmbH)
90
CellSystems Biotechnologie Vertrieb GmbH human retinal pericytes
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Human Retinal Pericytes, supplied by CellSystems Biotechnologie Vertrieb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pm20029988-67-0-6?v=CellSystems+Biotechnologie+Vertrieb+GmbH
Average 90 stars, based on 1 article reviews
human retinal pericytes - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
cultured bovine retinal capillary pericytes  (alcon inc)
90
alcon inc cultured bovine retinal capillary pericytes
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Cultured Bovine Retinal Capillary Pericytes, supplied by alcon inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pm02065725-8-75-47?v=alcon+inc
Average 90 stars, based on 1 article reviews
cultured bovine retinal capillary pericytes - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
bovine retinal capillary pericytes  (Verlag GmbH)
90
Verlag GmbH bovine retinal capillary pericytes
FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) <t>HRPCs</t> were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.
Bovine Retinal Capillary Pericytes, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retinal+pericytes/pm09049475-17-28-14?v=Verlag+GmbH
Average 90 stars, based on 1 article reviews
bovine retinal capillary pericytes - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) HRPCs were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.

Journal: Investigative ophthalmology & visual science

Article Title: Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases.

doi: 10.1167/iovs.19-26936

Figure Lengend Snippet: FIGURE 2. Apratoxin S4 inhibits HRPC activation. (a) HRPCs were treated with 25 nM Apratoxin S4 or 10 lg/mL aflibercept for 24 hours. Representative Western blot demonstrated a reduced level of PDGFRb in 10 nM Apratoxin S4–treated HRPCs (n ¼ 3). (b) AlamarBlue assay demonstrated reduced HRPC proliferation after treatment with 1 and 10 nM Apratoxin S4 for 24 hours (n ¼ 3). (c) DAPI staining (left) and quantitative analysis (right) of the motility of Apratoxin S4–treated HRPCs (n ¼ 3). After 4 hours of treatment of Apratoxin S4, HRPCs motility was reduced in a dose-dependent manner. Scale bar: 50 lM. (d) HRECs and HRPCs were co-cultured and treated with Apratoxin S4 for 16 hours. Representative images (left) and quantification of Apratoxin S4’s impact on HRPC (red) to HREC (green) ratio and total tube length (right) in Matrigel (n ¼ 3). Scale bar, 200 lM. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Primary human retinal endothelial cells (HRECs) and primary human retinal pericytes (HRPCs) were purchased from AngioProteomie (Boston, MA, USA) and maintained in endothelial growth media (EGM) or pericyte growth media (PGM) according to supplier’s instruction.

Techniques: Activation Assay, Western Blot, Alamar Blue Assay, Staining, Cell Culture

FIGURE 5. Apratoxin S4 specifically inhibits pathological neovascularization in the eye. (a) In OIR, Apratoxin S4 significantly decreased the formation of pathological neovascular tufts (delineated in higher power by white boundary line) without affecting the organized normal revascularization at P17. Scale bar: 500 lM (retina tile images) and 100 lM (higher magnification images). Vehicle, n ¼ 6; Apratoxin S4, n ¼ 6 per dosage. (b) Representative image and volume-rendered examples of NG2 (red) and CD31 (green) stained abnormal neovascular tufts as well as quantitative analysis of pericyte versus EC ratio in P17 OIR retina flatmount prepared from mice subjected to 0.0625 mg/kg Apratoxin S4 or vehicle treatment. Scale bar: 10 lM. (c) Representative Western blot demonstrating a reduced level of pSmad1, 5, 8 in P17 OIR retinal tissue prepared from Apratoxin S4–treated mice (n ¼ 3). (d) Combination of Apratoxin S4 and aflibercept in OIR in C57BL/6J mice resulted in enhanced reduction of neovascular tufts compared with single treatment, whereas organized revascuarization is not affect. Scale bar: 500 lM (retina tile images) and 100 lM (higher magnification images), n ¼ 6 per group. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.5, **P < 0.01, ***P < 0.001.

Journal: Investigative ophthalmology & visual science

Article Title: Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases.

doi: 10.1167/iovs.19-26936

Figure Lengend Snippet: FIGURE 5. Apratoxin S4 specifically inhibits pathological neovascularization in the eye. (a) In OIR, Apratoxin S4 significantly decreased the formation of pathological neovascular tufts (delineated in higher power by white boundary line) without affecting the organized normal revascularization at P17. Scale bar: 500 lM (retina tile images) and 100 lM (higher magnification images). Vehicle, n ¼ 6; Apratoxin S4, n ¼ 6 per dosage. (b) Representative image and volume-rendered examples of NG2 (red) and CD31 (green) stained abnormal neovascular tufts as well as quantitative analysis of pericyte versus EC ratio in P17 OIR retina flatmount prepared from mice subjected to 0.0625 mg/kg Apratoxin S4 or vehicle treatment. Scale bar: 10 lM. (c) Representative Western blot demonstrating a reduced level of pSmad1, 5, 8 in P17 OIR retinal tissue prepared from Apratoxin S4–treated mice (n ¼ 3). (d) Combination of Apratoxin S4 and aflibercept in OIR in C57BL/6J mice resulted in enhanced reduction of neovascular tufts compared with single treatment, whereas organized revascuarization is not affect. Scale bar: 500 lM (retina tile images) and 100 lM (higher magnification images), n ¼ 6 per group. All images shown are representative and data are represented as means 6 SEM; 1-way ANOVA followed by Tukey’s multiple comparisons test, *P < 0.5, **P < 0.01, ***P < 0.001.

Article Snippet: Primary human retinal endothelial cells (HRECs) and primary human retinal pericytes (HRPCs) were purchased from AngioProteomie (Boston, MA, USA) and maintained in endothelial growth media (EGM) or pericyte growth media (PGM) according to supplier’s instruction.

Techniques: Staining, Western Blot